株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アルツハイマー病:パイプライン分析

Alzheimer's Disease - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232776
出版日 ページ情報 英文 1284 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
アルツハイマー病:パイプライン分析 Alzheimer's Disease - Pipeline Review, H2 2016
出版日: 2016年08月10日 ページ情報: 英文 1284 Pages
概要

アルツハイマー病は、進行性で徐々に症状が悪化していく疾患で、神経が侵されることで記憶と行動に障害が起こります。 神経は、信号の伝送の原因となる神経伝達物質アセチルコリンの合成を行うため、破壊されると信号伝達が断絶されて最終的に記憶と行動機能に障害が出てきます。年齢、遺伝、循環器疾患、糖尿病、環境的要因など、様々な要因でアルツハイマー病発症のリスクが高まります。様々な合併症を引き起こすこともあり、治療せずに放置しておくと致命的になることもあります。

当レポートでは、アルツハイマー病の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • アルツハイマー病 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8356IDB

Summary

Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H2 2016', provides an overview of the Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
  • The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects
  • The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Alzheimer's Disease Overview
  • Therapeutics Development
  • Alzheimer's Disease - Therapeutics under Development by Companies
  • Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes
  • Alzheimer's Disease - Pipeline Products Glance
  • Alzheimer's Disease - Products under Development by Companies
  • Alzheimer's Disease - Products under Investigation by Universities/Institutes
  • Alzheimer's Disease - Companies Involved in Therapeutics Development
  • Alzheimer's Disease - Therapeutics Assessment
  • Drug Profiles
  • Alzheimer's Disease - Dormant Projects
  • Alzheimer's Disease - Discontinued Products
  • Alzheimer's Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Alzheimer's Disease, H2 2016
  • Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Development by Companies, H2 2016 (Contd..19)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..9)
  • Alzheimer's Disease - Pipeline by AB Science SA, H2 2016
  • Alzheimer's Disease - Pipeline by AbbVie Inc, H2 2016
  • Alzheimer's Disease - Pipeline by AC Immune SA, H2 2016
  • Alzheimer's Disease - Pipeline by Accera, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Acelot, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Actinogen Limited, H2 2016
  • Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Alzheimer's Disease - Pipeline by Affibody AB, H2 2016
  • Alzheimer's Disease - Pipeline by AFFiRiS AG, H2 2016
  • Alzheimer's Disease - Pipeline by Alector LLC, H2 2016
  • Alzheimer's Disease - Pipeline by Alkermes Plc, H2 2016
  • Alzheimer's Disease - Pipeline by Allergan Plc, H2 2016
  • Alzheimer's Disease - Pipeline by Allinky Biopharma, H2 2016
  • Alzheimer's Disease - Pipeline by ALSP, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H2 2016
  • Alzheimer's Disease - Pipeline by Alzinova AB, H2 2016
  • Alzheimer's Disease - Pipeline by AlzProtect SAS, H2 2016
  • Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Amgen Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Alzheimer's Disease - Pipeline by Aphios Corporation, H2 2016
  • Alzheimer's Disease - Pipeline by Apodemus AB, H2 2016
  • Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences, S.L., H2 2016
  • Alzheimer's Disease - Pipeline by Araclon Biotech, S.L., H2 2016
  • Alzheimer's Disease - Pipeline by Archer Pharmaceuticals, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by ArmaGen Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Artery Therapeutics, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by AskAt Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Astellas Pharma Inc., H2 2016
  • Alzheimer's Disease - Pipeline by AstraZeneca Plc, H2 2016
  • Alzheimer's Disease - Pipeline by Asubio Pharma Co., Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Ausio Pharmaceuticals, LLC, H2 2016
  • Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H2 2016
  • Alzheimer's Disease - Pipeline by Axovant Sciences Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Axsome Therapeutics, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Axxam SpA, H2 2016
  • Alzheimer's Disease - Pipeline by Beactica AB, H2 2016
  • Alzheimer's Disease - Pipeline by Berg LLC, H2 2016
  • Alzheimer's Disease - Pipeline by BioArctic Neuroscience AB, H2 2016
  • Alzheimer's Disease - Pipeline by Bioasis Technologies Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Biogen Inc, H2 2016
  • Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H2 2016
  • Alzheimer's Disease - Pipeline by Bionature E.A. Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Alzheimer's Disease - Pipeline by Bsim2, H2 2016
  • Alzheimer's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Carna Biosciences, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016
  • Alzheimer's Disease - Pipeline by Clera Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Cognition Therapeutics, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Cognosci, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by CohBar, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Corium International, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Coronis Partners Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Crossbeta Biosciences B.V., H2 2016
  • Alzheimer's Disease - Pipeline by D-Pharm Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Alzheimer's Disease - Pipeline by Daval International Limited, H2 2016
  • Alzheimer's Disease - Pipeline by DermaXon, LLC, H2 2016
  • Alzheimer's Disease - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by Eli Lilly and Company, H2 2016
  • Alzheimer's Disease - Pipeline by Emergent BioSolutions Inc., H2 2016
  • Alzheimer's Disease - Pipeline by EncephRx, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Endece, LLC, H2 2016
  • Alzheimer's Disease - Pipeline by ENKAM Pharmaceuticals A/S, H2 2016
  • Alzheimer's Disease - Pipeline by Ensemble Therapeutics Corporation, H2 2016
  • Alzheimer's Disease - Pipeline by Ensol Biosciences Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Epigen Biosciences, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Euroscreen S.A., H2 2016
  • Alzheimer's Disease - Pipeline by Evotec AG, H2 2016
  • Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Genentech, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2016
  • Alzheimer's Disease - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Alzheimer's Disease - Pipeline by GliaCure Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Glialogix, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Golden Biotechnology Corp., H2 2016
  • Alzheimer's Disease - Pipeline by Grifols, S.A., H2 2016
  • Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016
  • Alzheimer's Disease - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Alzheimer's Disease - Pipeline by HitGen LTD, H2 2016
  • Alzheimer's Disease - Pipeline by Humanetics Corporation, H2 2016
  • Alzheimer's Disease - Pipeline by Ichor Medical Systems, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Icure Pharmaceutical Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Immungenetics AG, H2 2016
  • Alzheimer's Disease - Pipeline by Impel NeuroPharma, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by ImStar Therapeutics Inc., H2 2016
  • Alzheimer's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Alzheimer's Disease - Pipeline by IntelGenx Corp., H2 2016

List of Figures

  • Number of Products under Development for Alzheimer's Disease, H2 2016
  • Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top